The FDA has issued emergency use authorizations for two monoclonal antibody treatments for COVID-19 – one produced by Eli Lilly and another by Regeneron. As science correspondent Richard Harris explains, emergency use authorization doesn't assure that these new drugs are effective, but that their potential benefits are likely to outweigh the risks. So today, we get to the bottom of how this type of treatment works and if they'll really make a difference.Email the show your questions, coronavirus or otherwise, at [email protected] more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from Short Wave
Transcribed and ready to explore now
Parasites Have Haunted Us For Millions Of Years
24 Oct 2025
Short Wave
Migrating Birds Have a Big, Clear Problem
22 Oct 2025
Short Wave
We Have the Cure. Why is Tuberculosis Still Around?
21 Oct 2025
Short Wave
Should Scientists Genetically Engineer Wild Species?
20 Oct 2025
Short Wave
Science Says Quitting Smoking At Any Age Is Good For The Brain
17 Oct 2025
Short Wave
What Happens When You're Under Anesthesia?
15 Oct 2025
Short Wave